Our Story

Co-Creator Of Diagnostic Ecosystem

Fapon Biotech will make every effort to fulfil the mission to "Empowering Timely, Accurate and Affordable Diagnosis for All", and provide better products and services to users with the focus on the needs and trends of biotechnology.

Phase I (2001–2008)

Built the core technology platform of IVD raw materials, established the domestic leading position in the field of infectious disease diagnostic raw materials, and successfully entered global markets.

  • Phase I (2001–2008)

  • Phase II (2009–2016)

  • Phase III (2017–2020)

  • Phase Ⅳ (2021–Present)

  • Technology

    Realized recombinant protein expression by recombinant DNA and genetic engineering, built and perfected the prokaryotic and yeast expression platform; mastered the technology of the purification of prokaryotic and eukaryotic expressed protein, as well as the renaturation technology of protein, to develop antigen-based diagnostic raw materials; built platforms for monoclonal antibody development and colloidal gold detection, etc., and initiated exploration of one-stop solutions in 2007, laying the foundation for the raw materials diversification and the development of one-stop solutions.
  • Products

    Diagnostic raw materials developed by Fapon Biotech for major infectious diseases such as HIV, HCV and TP were launched, covering the two traditional mainstream testing platforms of ELISA and colloidal gold.
  • Innovation & Intellectual Property

    Innovation ability was fully recognized in this phase when it was approved by the government as a high-tech enterprise in Shenzhen in 2005, and awarded the "Champion of the First Innovation Nanshan Entrepreneurs Star Contest" and the "Shenzhen Science and Technology Innovation Award" in 2008.
  • Market

    Established the leading position in the field of infectious disease diagnostic by marketing raw materials such as HIV, HCV, TP. Also entered international markets in 2007.

Phase II (2009–2016)

The period of application platform expansion and underlying platform construction, providing clients with products and services of raw materials to one-stop solutions.

  • Phase I (2001–2008)

  • Phase II (2009–2016)

  • Phase III (2017–2020)

  • Phase Ⅳ (2021–Present)

  • Technology

    During this phase, Fapon Biotech's technological development was reflected in two main areas:

    1. The establishment and improvement of biotechnology platforms: the polyclonal antibodies and baculovirus-insect expression systems, mammalian expression systems, genetically engineered recombinant antibodies and other biotechnology platforms were established. A variety of platforms for physical and chemical analysis, such as mass spectrometry, high-performance liquid chromatography, ultra-performance liquid chromatography and capillary electrophoresis, were also founded to guide the development of R&D pipelines and realize the improvement of product performance and quality control levels.

    2. The construction of a series of testing platforms: completed the construction of immunoturbidimetry, latex-enhanced immunoturbidimetry, fluorescence-based qPCR, CLIA, sequencing and others, which was equipped with the reagent raw material R&D capability of most testing methodology in the field of IVD. While improving the raw material testing and screening capabilities, the technology of the reagent solution was accumulated.
  • Products

    Developed strong product lines of enzyme-linked immunoassay, chemiluminescence, rapid test, molecular diagnostics, biochemistry, etc., covering mainstream disease detection materials. Among them, cTnI, malaria, CA 15-3 and many other products were received high recognization from customers because of the excellent performance.
  • Innovation & Intellectual Property

    Being certified as a national high-tech enterprise and won the "Guangdong Science and Technology Progress Award" and the "Shenzhen Science and Technology Innovation Award" in 2009. Different project was approved in 2010 and 2011 as the "National Torch Plan" in 2010 and 2011. Another product was certified as a key new product of Guangdong province.
  • Market

    Maintained the position as the leading domestic supplier of IVD raw materials while gradually expanding international markets. Fapon Biotech had become a mainstream raw material supplier to emerging markets and had entered markets of developed countries such as Europe and the US. Fapon Biotech became a representative brand in the industry for the global export of Chinese IVD raw materials.

Phase III (2017–2020)

Focuses on instrument and reagent platform development, and actively promotes diagnostic platform construction, gradually to form a comprehensive product line of one-stop solutions.

  • Phase I (2001–2008)

  • Phase II (2009–2016)

  • Phase III (2017–2020)

  • Phase Ⅳ (2021–Present)

  • Technology

    Guided by the value of "Future Anticipation", insight of future development trend, industry pain points, and our accumulation, Fapon Biotech integrates cutting-edge technologies through the mode of "co-creation and sharing" to provide clients with high-performance, low-cost instrument and reagent solutions, building a highly efficient diagnostic ecosystem. Since 2017, Fapon Biotech has focused on building an instrument platform represented by fully automatic CLIA analyzers and a series of reagent platforms for CLIA, biochemical diagnosis and molecular diagnosis.
  • Products

    During this phase, Fapon Biotech's product development was reflected in two main areas:

    1. Further diversification of raw materials: Fapon Biotech continued to invest resources in raw material R&D projects based on the demand of general health management and market trend, introducing a series of new raw materials with continuous optimization, such as AMH, PG I/II, HbA1c, cTnI, SAA, Malaria, influenza A, Dengue, NGS, etc.

    2. Formation of a series of one-stop solutions: the one-stop solutions of fully automated CLIA analyzer and reagent service, molecular diagnosis and biochemical diagnosis were formally introduced to the market. The business model of "Instrument + Reagent Service + Raw Material" with personalized cooperation schemes had created a new concept of one-stop solutions.
  • Innovation & Intellectual Property

    In 2018, an HIV patented product won the Chinese Patent Silver Award; in 2020, patented Taq Polymerase won the Guangdong Province Patent Gold Award, and Fapon Biotech became a Shenzhen Patent Advantage Enterprise and a Guangdong Province Intellectual Property Demonstration Enterprise. Fapon Biotech pays great attention to patent application and intellectual property protection. By the end of June 2020, Fapon Biotech applied for 377 patents with 80% for invention.
  • Market

    Reached strategic cooperation with many well-known domestic enterprises through the fully automatic CLIA analyzer, and the instrument platform construction has achieved initial success. Meanwhile, the advantages of one-stop solution that Fapon Biotech focused on forging were fully reflected in the COVID-19 pandemic in 2020. Fapon Biotech is the mainstream supplier of COVID-19 PCR and antigen tests. Its raw materials and semi-finished products support a smooth supply of diagnostic reagents to the end market, helped pandemic responses over hundreds of IVD partners in the world.

Phase Ⅳ (2021–Present)

Enhance IVD technologies and join hands with global partners to build a diagnostic ecosystem

  • Phase I (2001–2008)

  • Phase II (2009–2016)

  • Phase III (2017–2020)

  • Phase Ⅳ (2021–Present)

  • IVD Ecosystem



    During this phase, Fapon Biotech takes the lead in building a diagnostic ecosystem. Based on the principle of not directly involving into the terminal market, it integrates powerful bodies such as the government, customs, universities, medical institutions, scientific research institutes and so on to make every effort to place more open instruments for IVD ecoststem partners. Fapon Biotech's core technical capabilities of core raw materials, reagent solutions, and open instrument platforms, combined with excellent ecosystem services and incubation funds, have provide fertile soil for the growth of enterprises partner in the IVD ecosystem, jointly creating open and inclusive industry environment for resource sharing.


  • Innovation & Intellectual Property



    In 2021, "Fapon" has been included in the Guangdong Province Key Trademark Protection List; At this phase, Fapon Biotech pays more attention to patent application and intellectual property protection. In 2022, its key technology of IVD reagents bioactive protein won the "Second Prize of Guangdong Science and Technology Progress Awards". As of May 31, 2022, the total number of Fapon Biotech's patents reached 573, of which inventions accounted for more than 80%.


  • Open Instrument Platforms and Product Breakthroughs


    Fapon Biotech has deployed instrument platforms on NGS and POCT molecular diagnostics, with design idea to connect upstream developers and downstream application users in an open operation mode, accelerating technologies innovations and product iterations, so as to meet the urgent needs of many IVD companies and terminal users. Sequlite, a wholly-owned subsidiary of Fapon Biotech, has completed the research and development of the first functional prototype of a desktop mid-to-low-throughput gene sequencing instrument, and is currently testing and optimizing the beta model in the commercialization stage. RunPon Bioscience, a subsidiary of Fapon Biotech, has completed the registration inspection of the first mass-produced PCR analyzer model and is pending approval of the registration certificate.

    Fapon Biotech innovatively operates the chemiluminescence analyzers in open mode. On one hand, it helps R&D and production enterprises of chemiluminescence reagents to build complete chemiluminescence instrument and reagent systems more efficiently, and apply to terminal medical testing institutions, accelerating their enterance of the chemiluminescence market. On the other hand, Fapon Biotech also share the instrument platform to the third-party reagent developers to promote the development of adapting reagents and  transformation to clinical applications in a more efficient way. This will help promote industrial chain collaboration, reduce instrument development costs, as well as improve industry operational efficiency.

    In addition, Fapon Biotech has launched complete COVID-19 testing solutions which cover various testing application scenarios. It provides IVD enterprises with one-stop COVID-19 detection technologies and services ranging from reagent raw materials, semi-finished products to technical support, registration assistance, etc., empoweing local diagnostics industrial level. Fapon Biotech closely tracks any emergence of new variant and continuously improves the raw materials for antigen test. At present, its antibody raw material for antigen test has iterated to fifth-generation.

  • Market

    Over 20 years of development, Fapon Biotech has become an influential supplier of IVD reagent raw materials and solutions worldwide. In recent years, Fapon Biotech's international business revenue accounts for about 40%, winning trust from over 1,500 business partners around the world, and its products are widely sold to 61 countries and regions in Europe, America, Asia, Australia, Africa, etc.